Tacrolimus is an immunosuppressive agent used in solid organ and islet transplantation. Its topical form has shown benefit in the treatment of inflammatory skin conditions. Although tacrolimus has a wide spectrum of side effects, dermatological complications related to systemic tacrolimus therapy are limited in the literature. Atopic dermatitis (AD) is a chronic pruritic cutaneous condition that usually begins in infancy and is characterized by an increased Th2 response. We report the case of a patient with type 1 diabetes mellitus (T1DM) and history of AD latent for 10 years who developed severe dermatitis and alopecia 5 months after undergoing allogeneic islet transplantation and initiating a steroid-free immunosuppressive regimen with sirolimus and tacrolimus maintenance. After exclusion of other possible causes for the progression and exacerbation of the clinical presentation of AD, discontinuation of tacrolimus and introduction of mycophenolate mofetil resulted in full remission of the symptoms. The beneficial effects of tacrolimus withdrawal suggest a cause-effect relationship between this adverse event and the utilization of the drug. Islet graft function remained stable after modification of the therapeutic regimen (stable glycemic control and unchanged C-peptide).Key words: Atopic dermatitis; Alopecia areata; Diabetes; Immunosuppression; Islet transplantation; Tacrolimus
INTRODUCTIONbetes quality of life (41) is commonly observed in patients with T1DM after islet transplantation, which is the direct consequence of improved glycemic control and Transplantation of allogeneic islets is currently limited to patients with type 1 diabetes mellitus (T1DM) reduced fear of hypoglycemia. The steady progress of the islet transplantation field with hypoglycemia unawareness and unstable glycemic control (8,24,34,40,45,47,48,52,56,57). The most remarkhas led to increased success both in islet cell processing and clinical outcome in recent years (37,45). Very promable benefits of islet transplantation include improved glycemic control (with normalization of glycated hemoising approaches are under development aiming at improving the efficiency of organ recovery and islet isolation globin A1c and reduction of glycemic excursion throughout the day) (20) and prevention of severe hypoglycemic techniques (6,15,19,50,54,59,63,67), enhancing engraftment through cytoprotection of islet grafts (27,28,35, episodes (1,40,51,53), even when exogenous insulin is required (i.e., marginal islet graft function) (8,24,34,40,38,68), islet implantation into alternative sites (7,23,39), implementation of immunomodulatory (38,43) and im-45,47,48,52,56,57 munoisolation (30,31) protocols to reduce the need for mated digestion method followed by density gradient purification was used (15,26,46). Islets were then transchronic immunosuppression (47). Meanwhile, increasing efforts have been focused toward the identification of planted intrahepatically by percutaneous catheterization of the portal vein using the bag technique (3,18). safe and unl...